Trial Profile
Phase II Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor Positive Breast Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs MK 2206 (Primary) ; Exemestane; Goserelin
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 28 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 28 Feb 2011 Actual initiation date changed from Jan 2011 to Feb 2011 as reported by ClinicalTrials.gov.
- 22 Dec 2010 Planned end date changed from 1 Jun 2016 to 1 Dec 2012 as reported by ClinicalTrials.gov.